Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off‐Target Toxicity
Abstract Immune‐stimulating antibody conjugate (ISACs) incorporating STING agonists as payloads leverage both the targeting capability of the Fab region and the Fc region‐mediated tumor antigen‐dependent immune activation. Herein, a novel class of ISACs is reported, generated by engineering a quater...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202502270 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227317140783104 |
|---|---|
| author | Yu Long Borui Tang Fei Xie Lianqi Liu Yangyihua Zhou Jingwen Dong Jianfeng Wang Cuicui Sun Yuting Wang Ruoqi Li Na Zhang Liping Li Longlong Luo Junhai Xiao Wu Zhong Dian Xiao Hongbin Deng Xinbo Zhou |
| author_facet | Yu Long Borui Tang Fei Xie Lianqi Liu Yangyihua Zhou Jingwen Dong Jianfeng Wang Cuicui Sun Yuting Wang Ruoqi Li Na Zhang Liping Li Longlong Luo Junhai Xiao Wu Zhong Dian Xiao Hongbin Deng Xinbo Zhou |
| author_sort | Yu Long |
| collection | DOAJ |
| description | Abstract Immune‐stimulating antibody conjugate (ISACs) incorporating STING agonists as payloads leverage both the targeting capability of the Fab region and the Fc region‐mediated tumor antigen‐dependent immune activation. Herein, a novel class of ISACs is reported, generated by engineering a quaternary ammonium‐cleavable linker to conjugate diABZI STING agonist 3 (dSA3) with the HER2‐targeting antibody Trastuzumab. The optimized ISAC (TZ‐dSA3‐12) demonstrated high potency, stability, enhanced solubility, and reduced off‐target toxicity. The data showed that TZ‐dSA3‐12 potently activates the STING pathway in the tumor microenvironment through the synergistic action of the Fab and Fc regions of antibodies (activity switch‐on). In contrast, TZ‐dSA3‐12 exhibited ≈75 fold lower activity than dSA3 in normal immune cells, where activation relies solely on the Fc region without Fab‐mediated tumor antigen binding (activity switch‐off). Furthermore, systemic administration of TZ‐dSA3‐12 at a dose (1 mg kg−1) elicited robust and sustained antitumor effect in a manner dependent on the activation of innate immunity and adaptive immunity, including macrophages, dendritic cells (DCs) and CD8+ T cells, while minimizing systemic cytokine release. Notably, TZ‐dSA3‐12 also induced immunological memory to combat the growth of rechallenged tumors. This innovative quaternary ammonium‐linked STING agonist‐ISAC represents a promising avenue for the future development of STING‐targeted immunotherapy. |
| format | Article |
| id | doaj-art-c32a48e95cb7457c9bdcef8cd1d6367a |
| institution | Kabale University |
| issn | 2198-3844 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj-art-c32a48e95cb7457c9bdcef8cd1d6367a2025-08-23T14:15:47ZengWileyAdvanced Science2198-38442025-08-011231n/an/a10.1002/advs.202502270Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off‐Target ToxicityYu Long0Borui Tang1Fei Xie2Lianqi Liu3Yangyihua Zhou4Jingwen Dong5Jianfeng Wang6Cuicui Sun7Yuting Wang8Ruoqi Li9Na Zhang10Liping Li11Longlong Luo12Junhai Xiao13Wu Zhong14Dian Xiao15Hongbin Deng16Xinbo Zhou17College of Pharmacy Qingdao University Qingdao 266071 ChinaSchool of Pharmaceutical Sciences Capital Medical University Beijing 100069 ChinaNational Engineering Research Center for the Emergency Drug Academy of Military Medical Sciences Beijing 100850 ChinaNational Engineering Research Center for the Emergency Drug Academy of Military Medical Sciences Beijing 100850 ChinaAcademy of Military Medical Sciences Beijing 100850 ChinaInstitute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100050 ChinaNational Engineering Research Center for the Emergency Drug Academy of Military Medical Sciences Beijing 100850 ChinaInstitute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100050 ChinaInstitute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100050 ChinaInstitute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100050 ChinaInstitute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100050 ChinaInstitute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100050 ChinaAcademy of Military Medical Sciences Beijing 100850 ChinaNational Engineering Research Center for the Emergency Drug Academy of Military Medical Sciences Beijing 100850 ChinaNational Engineering Research Center for the Emergency Drug Academy of Military Medical Sciences Beijing 100850 ChinaNational Engineering Research Center for the Emergency Drug Academy of Military Medical Sciences Beijing 100850 ChinaInstitute of Medicinal Biotechnology Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100050 ChinaNational Engineering Research Center for the Emergency Drug Academy of Military Medical Sciences Beijing 100850 ChinaAbstract Immune‐stimulating antibody conjugate (ISACs) incorporating STING agonists as payloads leverage both the targeting capability of the Fab region and the Fc region‐mediated tumor antigen‐dependent immune activation. Herein, a novel class of ISACs is reported, generated by engineering a quaternary ammonium‐cleavable linker to conjugate diABZI STING agonist 3 (dSA3) with the HER2‐targeting antibody Trastuzumab. The optimized ISAC (TZ‐dSA3‐12) demonstrated high potency, stability, enhanced solubility, and reduced off‐target toxicity. The data showed that TZ‐dSA3‐12 potently activates the STING pathway in the tumor microenvironment through the synergistic action of the Fab and Fc regions of antibodies (activity switch‐on). In contrast, TZ‐dSA3‐12 exhibited ≈75 fold lower activity than dSA3 in normal immune cells, where activation relies solely on the Fc region without Fab‐mediated tumor antigen binding (activity switch‐off). Furthermore, systemic administration of TZ‐dSA3‐12 at a dose (1 mg kg−1) elicited robust and sustained antitumor effect in a manner dependent on the activation of innate immunity and adaptive immunity, including macrophages, dendritic cells (DCs) and CD8+ T cells, while minimizing systemic cytokine release. Notably, TZ‐dSA3‐12 also induced immunological memory to combat the growth of rechallenged tumors. This innovative quaternary ammonium‐linked STING agonist‐ISAC represents a promising avenue for the future development of STING‐targeted immunotherapy.https://doi.org/10.1002/advs.202502270antitumor immunitydiABZI STING agonist 3immune‐stimulating antibody conjugatesquaternary ammonium salt‐linkerstimulator of interferon genes |
| spellingShingle | Yu Long Borui Tang Fei Xie Lianqi Liu Yangyihua Zhou Jingwen Dong Jianfeng Wang Cuicui Sun Yuting Wang Ruoqi Li Na Zhang Liping Li Longlong Luo Junhai Xiao Wu Zhong Dian Xiao Hongbin Deng Xinbo Zhou Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off‐Target Toxicity Advanced Science antitumor immunity diABZI STING agonist 3 immune‐stimulating antibody conjugates quaternary ammonium salt‐linker stimulator of interferon genes |
| title | Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off‐Target Toxicity |
| title_full | Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off‐Target Toxicity |
| title_fullStr | Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off‐Target Toxicity |
| title_full_unstemmed | Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off‐Target Toxicity |
| title_short | Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off‐Target Toxicity |
| title_sort | novel quaternary ammonium salt linked sting agonist antibody drug conjugate synergistic activation of tumor immunity with mitigated off target toxicity |
| topic | antitumor immunity diABZI STING agonist 3 immune‐stimulating antibody conjugates quaternary ammonium salt‐linker stimulator of interferon genes |
| url | https://doi.org/10.1002/advs.202502270 |
| work_keys_str_mv | AT yulong novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT boruitang novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT feixie novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT lianqiliu novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT yangyihuazhou novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT jingwendong novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT jianfengwang novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT cuicuisun novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT yutingwang novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT ruoqili novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT nazhang novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT lipingli novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT longlongluo novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT junhaixiao novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT wuzhong novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT dianxiao novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT hongbindeng novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity AT xinbozhou novelquaternaryammoniumsaltlinkedstingagonistantibodydrugconjugatesynergisticactivationoftumorimmunitywithmitigatedofftargettoxicity |